Peregrine Pharmaceuticals reported $200.78M in Current Assets for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Assets Change
Acceleron Pharma XLRN:US $ 696.61M 21.16M
Adamas Pharmaceuticals ADMS:US 108M 7.65M
Amgen AMGN:US $ 24380M 5281M
AstraZeneca AZN:LN 26.69B 583M
Bristol Myers Squibb BMY:US $ 31443M 2282M
Celldex Therapeutics CLDX:US $ 426.56M 258.95M
Chemocentryx CCXI:US $ 293.38M 23.75M
Dicerna Pharmaceuticals DRNA:US $ 589M 27.49M
Eli Lilly And LLY:US $ 17808.3M 512.8M
Flexion Therapeutics FLXN:US $ 192.76M 8.64M
GlaxoSmithKline GSK:LN 18.25B 688M
Immunogen IMGN:US $ 296.8M 22.41M
Intrexon XON:US $ 153.09M 3.59M
Karyopharm Therapeutics KPTI:US $ 241.58M 31.92M
Kindred Biosciences KIN:US 79.08M 8K
Macrogenics MGNX:US $ 334.7M 32.3M
Mannkind MNKD:US $ 159.21M 20.7M
Minerva Neurosciences NERV:US $ 67.44M 7.79M
Newlink Genetics NLNK:US 105.75M 7.72M
Novartis NOVN:VX 26.25B 2.45B
Novavax NVAX:US $ 2174.18M 180.81M
Peregrine Pharmaceuticals PPHM:US $ 200.78M 7.02M
Repligen RGEN:US $ 910.85M 72.98M
Xencor XNCR:US $ 329.63M 151.34M